ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för edelfosine. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 2014-05-01

1-O-octadecyl-2-O-methylglycero-3-phosphocholine (Edelfosine) and cancer cell invasion: a short review.

Van Slambrouck S, Steelant WF.

Anticancer Agents Med Chem · review; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.2174/1871520614666140309231505

Bibliografisk träff 2014-05-01

Edelfosine in membrane environment - the Langmuir monolayer studies.

Dynarowicz-Latka P, Hac-Wydro K.

Anticancer Agents Med Chem · review; journal article · DOI 10.2174/1871520614666140309230722

Bibliografisk träff 2014-05-01

Antitumoral alkylphospholipids alter cell lipid metabolism.

Marco C, Ríos-Marco P, Jiménez-López JM, Segovia JL, Carrasco MP.

Anticancer Agents Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/1871520614666140309224707

Bibliografisk träff 2014-05-01

Combining anti-tumor alkyl-phospholipid analogs and radiotherapy: rationale and clinical outlook.

Verheij M, Moolenaar WH, Blitterswijk WJ.

Anticancer Agents Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/1871520614666140309224145

Bibliografisk träff 2014-05-01

Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine.

Gajate C, Mollinedo F.

Anticancer Agents Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/1871520614666140309222259

Bibliografisk träff 2014-04-02

Influence of platelet-activating factor, lyso-platelet-activating factor and edelfosine on Langmuir monolayers imitating plasma membranes of cell lines differing in susceptibility to anti-cancer treatment: the effect of plasmalogen level.

Flasiński M, Hąc-Wydro K, Wydro P, Dynarowicz-Łątka P.

J R Soc Interface · research support, non-u.s. gov't; research-article; journal article · DOI 10.1098/rsif.2013.1103

Bibliografisk träff 2014-03-25

The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response.

Abramowski P, Otto B, Martin R.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0091970

Bibliografisk träff 2014-01-10

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.

Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS.

Blood Cancer J · research-article; journal article · DOI 10.1038/bcj.2013.69

Bibliografisk träff 2014-01-03

Novel hybrid selenosulfonamides as potent antileishmanial agents.

Baquedano Y, Moreno E, Espuelas S, Nguewa P, Font M, Gutierrez KJ, Jiménez-Ruiz A, Palop JA, Sanmartín C.

Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2013.12.030

Bibliografisk träff 2014-01-01

In vitro intestinal co-culture cell model to evaluate intestinal absorption of edelfosine lipid nanoparticles.

Lasa-Saracíbar B, Guada M, Sebastián V, Blanco-Prieto MJ.

Curr Top Med Chem · research support, non-u.s. gov't; journal article · DOI 10.2174/1568026614666140329225340

Bibliografisk träff 2013-12-01

The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine.

Varela-M RE, Mollinedo-Gajate C, Muro A, Mollinedo F.

Acta Trop · research support, non-u.s. gov't; journal article · DOI 10.1016/j.actatropica.2013.11.018

Bibliografisk träff 2013-06-24

Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.

Castro BM, Fedorov A, Hornillos V, Delgado J, Acuña AU, Mollinedo F, Prieto M.

J Phys Chem B · research support, non-u.s. gov't; journal article · DOI 10.1021/jp401407d

Bibliografisk träff 2013-04-30

Efficacy of edelfosine lipid nanoparticles in breast cancer cells.

Aznar MÁ, Lasa-Saracíbar B, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ.

Int J Pharm · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ijpharm.2013.04.068

Bibliografisk träff 2013-01-23

Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines.

Lasa-Saracíbar B, Estella-Hermoso de Mendoza A, Mollinedo F, Odero MD, Blanco-Príeto MJ.

Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2013.01.018

Bibliografisk träff 2012-11-16

Edelfosine and perifosine disrupt hepatic mitochondrial oxidative phosphorylation and induce the permeability transition.

Burgeiro A, Pereira CV, Carvalho FS, Pereira GC, Mollinedo F, Oliveira PJ.

Mitochondrion · research support, non-u.s. gov't; journal article · DOI 10.1016/j.mito.2012.11.003

Bibliografisk träff 1985-01-01

Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro.

Storme GA, Berdel WE, van Blitterswijk WJ, Bruyneel EA, De Bruyne GK, Mareel MM.

Cancer Res · research support, non-u.s. gov't; journal article